$Ovid Therapeutics (OVID.US)$ why the super dump?

Mcsnacks H Tupack : They reduced their workforce

70205719 : OVID announced that Takeda Pharmaceutical Company’s Phase 3 Skyline study of Soticlestat for Dravet syndrome missed its primary endpoint of reduction in convulsive seizure frequency and showed clinically meaningful and significant effects in multiple key secondary efficacy endpoints.